Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection

Basit Öğe Kaydı
dc.authorid0000-0003-2440-7529
dc.authorid0000-0002-3341-925X
dc.authorid0000-0003-0771-2505
dc.authorwosidKARAALİ, Rıdvan/AAQ-1018-2020
dc.contributor.authorDoğan, Mustafa
dc.contributor.authorTopçu, Birol
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorErdem, İlknur
dc.date.accessioned2022-05-11T14:13:59Z
dc.date.available2022-05-11T14:13:59Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik Ana Bilim Dalı
dc.description.abstractObjectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver disease due to hepatitis C virus (HCV) genotype 1b. Materials and Methods: This study included cases who were treated with DAAs after HCV genotype 1b infection. HCV-RNA levels and biochemical and hematological parameters measured at the beginning of treatment, 12th week and 52th week after the treatment were transferred to the SPSS statistics software. model for end-stage liver disease (MELD) and Child-Pugh scores were also calculated and added to these data. Results: The study group consisted of a total of 102 patients, including 33 (32%) males and 69 (68%) females. Compensated cirrhosis was detected in 26.5% of the patients (n=27). There was a significant change in serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alpha-fetoprotein (AFP) parameters in patients with compensated cirrhosis after treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALP and AFP parameters in the group without cirrhosis (p<0.05). Only a significant decrease was observed in the MELD score of the patients with compensated cirrhosis (p=0.007). Conclusion: The ombitasvir/paritaprevir/ritonavir+dasabuvir and ledipasvir/sofosbuvir regimens are very effective and safe in the treatment of patients who develop chronic liver disease and compensated liver cirrhosis after HCV genotype 1b infection.
dc.identifier.doi10.4274/vhd.galenos.2020.2020.0016
dc.identifier.endpage48
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue2en_US
dc.identifier.startpage43
dc.identifier.urihttps://doi.org/10.4274/vhd.galenos.2020.2020.0016
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5730
dc.identifier.volume26
dc.identifier.wosWOS:000573999000001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthorDoğan, Mustafa
dc.institutionauthorTopçu, Birol
dc.institutionauthorErdem, İlknur
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHCV
dc.subjectPrOD
dc.subjectMELD
dc.subjectChild-Pugh
dc.subjectcompensated cirrhosis
dc.subjectOmbitasvir/Paritaprevir/Ritonavir
dc.subjectEfficacy
dc.subjectRibavirin
dc.subjectDasabuvir
dc.titleEvaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5730.pdf
Boyut:
141.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu